{"id":123,"date":"2026-06-30T14:14:48","date_gmt":"2026-06-30T14:14:48","guid":{"rendered":"https:\/\/wp.odu.edu\/odupresentationtemplate\/?page_id=2"},"modified":"2026-06-30T14:27:17","modified_gmt":"2026-06-30T14:27:17","slug":"sample-page","status":"publish","type":"page","link":"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/","title":{"rendered":"Immunology ePortfolio"},"content":{"rendered":"<div class=\"container\">\n<p><!-- HEADER --><\/p>\n<div class=\"header\">\n<div>\n<h1>\ud83e\uddec Immunology ePortfolio<\/h1>\n<div class=\"sub\">Aayushi Tailor \u00b7 Biomedical Science \u00b7 June 2026<\/div>\n<\/div>\n<div class=\"badge\">\u23f3 Final \u00b7 Completion<\/div>\n<\/div>\n<p><!-- TABS --><\/p>\n<div class=\"tabs\"><button class=\"tab-btn active\" data-tab=\"tab-mab\">\ud83e\uddea mAb Drug<\/button><br \/>\n<button class=\"tab-btn\" data-tab=\"tab-covid\">\ud83e\udda0 COVID T-cell<\/button><br \/>\n<button class=\"tab-btn\" data-tab=\"tab-reflection\">\ud83d\udcd8 Reflection<\/button><br \/>\n<button class=\"tab-btn\" data-tab=\"tab-mid\">\ud83d\udccc Mid-Term Self-Eval<\/button><br \/>\n<button class=\"tab-btn\" data-tab=\"tab-vaccine\">\ud83d\udc89 Vaccine Mandate<\/button><br \/>\n<button class=\"tab-btn\" data-tab=\"tab-car\">\ud83e\uddeb CAR-T Therapy<\/button><\/div>\n<p><!-- =============================== --><br \/>\n<!-- PANEL 1: mAb Drug              --><br \/>\n<!-- =============================== --><\/p>\n<div id=\"tab-mab\" class=\"panel active\">\n<h2 class=\"section-title\">\ud83d\udc8a Tafasitamab (Monjuvi\u00ae) \u2014 mAb Profile<\/h2>\n<div class=\"card\">\n<h3>Drug Overview<\/h3>\n<p><strong>Generic:<\/strong> Tafasitamab-cxiv \u00b7 <strong>Brand:<\/strong> Monjuvi\u00ae<br \/>\n<strong>Developer:<\/strong> MorphoSys &amp; Incyte \u00b7 <strong>FDA approval:<\/strong> July 2020 (DLBCL), June 2025 (FL)<\/p>\n<\/div>\n<div class=\"grid-2\">\n<div class=\"card\">\n<h3>\ud83d\udccb Indications<\/h3>\n<p><strong>Relapsed\/Refractory DLBCL<\/strong><br \/>\nmost common non-Hodgkin lymphoma; used when ASCT not eligible.<\/p>\n<p><strong>Relapsed\/Refractory Follicular Lymphoma<\/strong><br \/>\nindolent B-cell lymphoma, after prior therapy failure.<\/p>\n<\/div>\n<div class=\"card\">\n<h3>\ud83d\udc89 Dosage &amp; Admin<\/h3>\n<p><strong>IV infusion<\/strong> \u00b7 12 mg\/kg actual body weight<br \/>\n28\u2011d cycles: Cycle1 (D1,4,8,15,22); C2\u20113 (D1,8,15,22); C4+ (D1,15)<\/p>\n<p><span class=\"inline-icon\">premed<\/span> acetaminophen, antihistamines, corticosteroids 30\u2011120 min prior.<\/p>\n<\/div>\n<\/div>\n<div class=\"card\">\n<h3>\u2695\ufe0f Side Effects<\/h3>\n<div class=\"grid-2\">\n<div><strong>Common<\/strong><\/p>\n<ul>\n<li>Neutropenia<\/li>\n<li>Fatigue<\/li>\n<li>Anemia<\/li>\n<li>Diarrhea<\/li>\n<li>Cough<\/li>\n<li>Fever<\/li>\n<li>Peripheral edema<\/li>\n<\/ul>\n<\/div>\n<div><strong>Serious<\/strong><\/p>\n<ul>\n<li>Severe infusion reactions<\/li>\n<li>Myelosuppression (infection\/bleeding risk)<\/li>\n<li>Infections<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"card\">\n<h3>\ud83e\uddec Antibody Class &amp; Structure<\/h3>\n<p><strong>Humanized IgG1<\/strong> monoclonal antibody. IgG1 \u2192 long half\u2011life (~3 weeks), strong immune recruitment.<\/p>\n<ul>\n<li><strong>Fab<\/strong> (variable tips): recognizes CD19 antigen.<\/li>\n<li><strong>Fc<\/strong> (stem): interacts with NK cells, complement \u2192 triggers cell death.<\/li>\n<\/ul>\n<\/div>\n<p><!-- ===== NEW MECHANISM DIAGRAM ===== --><\/p>\n<div class=\"card\">\n<h3>\ud83c\udfaf Mechanism of Action \u2014 CD19 targeting<\/h3>\n<p><a href=\"http:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-content\/uploads\/sites\/41387\/2026\/06\/Screenshot-2026-06-30-at-10.26.19\u202fAM.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-184\" src=\"http:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-content\/uploads\/sites\/41387\/2026\/06\/Screenshot-2026-06-30-at-10.26.19\u202fAM-300x191.png\" alt=\"\" width=\"300\" height=\"191\" srcset=\"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-content\/uploads\/sites\/41387\/2026\/06\/Screenshot-2026-06-30-at-10.26.19\u202fAM-300x191.png 300w, https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-content\/uploads\/sites\/41387\/2026\/06\/Screenshot-2026-06-30-at-10.26.19\u202fAM-1024x652.png 1024w, https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-content\/uploads\/sites\/41387\/2026\/06\/Screenshot-2026-06-30-at-10.26.19\u202fAM-768x489.png 768w, https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-content\/uploads\/sites\/41387\/2026\/06\/Screenshot-2026-06-30-at-10.26.19\u202fAM-1536x978.png 1536w, https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-content\/uploads\/sites\/41387\/2026\/06\/Screenshot-2026-06-30-at-10.26.19\u202fAM-2048x1304.png 2048w, https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-content\/uploads\/sites\/41387\/2026\/06\/Screenshot-2026-06-30-at-10.26.19\u202fAM-600x382.png 600w, https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-content\/uploads\/sites\/41387\/2026\/06\/Screenshot-2026-06-30-at-10.26.19\u202fAM-945x602.png 945w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>Binds CD19 on B\u2011cells (normal &amp; malignant), <em>not<\/em> on other tissues.<\/p>\n<div class=\"mech-diagram\"><!-- Step 1: Binding --><\/p>\n<div class=\"mech-row\">\n<div class=\"mech-box highlight\">\ud83e\uddec Cancer B-cell<br \/>\n<span style=\"font-weight: 400;font-size: 0.85rem\">(CD19+)<\/span><\/div>\n<p><span class=\"mech-arrow\">\u27f7<\/span><\/p>\n<div class=\"mech-box\" style=\"background: #dceafa\">\ud83d\udd17 Tafasitamab<br \/>\n<span style=\"font-weight: 400;font-size: 0.8rem\">(anti-CD19 mAb)<\/span><\/div>\n<p><span class=\"mech-arrow\">\u2192<\/span><\/p>\n<div class=\"mech-box highlight\" style=\"background: #cfe0f7\">\ud83c\udfaf Antibody\u2011antigen<br \/>\ncomplex<\/div>\n<\/div>\n<p><!-- Step 2: Effector mechanisms (branched) --><\/p>\n<div style=\"text-align: center;margin: 0.8rem 0 0.2rem;font-weight: 500;color: #1f4f7a\">\u2b07\ufe0f Immune effector mechanisms \u2b07\ufe0f<\/div>\n<div class=\"mech-branch\">\n<div class=\"mech-branch-item\"><span class=\"badge\">ADCC<\/span><br \/>\n<span class=\"desc\">NK cells release cytotoxic granules<\/span><\/div>\n<div class=\"mech-branch-item\"><span class=\"badge\">ADCP<\/span><br \/>\n<span class=\"desc\">Macrophages engulf &amp; digest<\/span><\/div>\n<div class=\"mech-branch-item\"><span class=\"badge\">Direct<\/span><br \/>\n<span class=\"desc\">Apoptosis signaling<\/span><\/div>\n<\/div>\n<p><!-- Step 3: Final outcome --><\/p>\n<div style=\"display: flex;justify-content: center;margin-top: 0.8rem\">\n<div class=\"mech-final\">\ud83d\udc80 CANCER CELL DEATH<\/div>\n<\/div>\n<div style=\"text-align: center;font-size: 0.85rem;color: #3d6382;margin-top: 0.3rem\">via ADCC \u00b7 ADCP \u00b7 direct cytotoxicity<\/div>\n<\/div>\n<ul style=\"margin-top: 0.8rem\">\n<li><strong>ADCC:<\/strong> Antibody\u2011dependent cell\u2011mediated cytotoxicity (NK cells).<\/li>\n<li><strong>ADCP:<\/strong> Antibody\u2011dependent cellular phagocytosis (macrophages).<\/li>\n<li><strong>Direct cytotoxicity:<\/strong> Apoptotic signals triggered by CD19 engagement.<\/li>\n<\/ul>\n<\/div>\n<div class=\"ref\">\n<p><strong>References<\/strong><br \/>\nSalles, G. et al. (2020). Tafasitamab + lenalidomide in R\/R DLBCL (L\u2011MIND). <em>Lancet Oncol<\/em> 21(7):978\u2011988.<br \/>\nNIH (2018). mAb structure. <em>Pharmaceutics<\/em> 10(3):83.<br \/>\nDanaher Life Sciences (2026). mAbs: mechanisms &amp; applications.<\/p>\n<\/div>\n<\/div>\n<p><!-- =============================== --><br \/>\n<!-- PANEL 2: COVID T-cell           --><br \/>\n<!-- =============================== --><\/p>\n<div id=\"tab-covid\" class=\"panel\">\n<h2 class=\"section-title\">\ud83e\udda0 COVID\u201119 Vaccine &amp; T\u2011cell Immunity<\/h2>\n<div class=\"card\">\n<p><strong>Summary of Wherry &amp; Barouch (2022), <em>Science<\/em><\/strong><br \/>\nwhile neutralizing antibodies (NAbs) are important, T cells provide durable protection against severe disease and variants.<\/p>\n<\/div>\n<p><!-- ===== COVID MECHANISM DIAGRAM ===== --><\/p>\n<div class=\"card\">\n<h4>\ud83e\udde9 How T cells provide protection<\/h4>\n<div class=\"covid-flow\"><span class=\"step\">\ud83d\udc89 Vaccine<\/span><br \/>\n<span class=\"arrow\">\u2192<\/span><br \/>\n<span class=\"step\">\ud83e\uddec Antigen presentation<br \/>\n<span style=\"font-weight: 400;font-size: 0.8rem\">(MHC I\/II)<\/span><\/span><br \/>\n<span class=\"arrow\">\u2192<\/span><br \/>\n<span class=\"step\">\ud83d\udee1\ufe0f CD8+ CTL<\/span><br \/>\n<span class=\"arrow\">+<\/span><br \/>\n<span class=\"step\">\ud83e\uddeb CD4+ Th<\/span><br \/>\n<span class=\"arrow\">\u2192<\/span><br \/>\n<span class=\"step\" style=\"background: #dceafa;border-color: #1b6bb0\">\u2705 Kill infected cells<br \/>\n\u2795 Cytokines<\/span><\/div>\n<div style=\"display: flex;flex-wrap: wrap;justify-content: center;gap: 0.8rem 2rem;margin-top: 1rem\">\n<div><span style=\"background: #1b6bb0;color: white;padding: 0.1rem 0.8rem;border-radius: 30px\">CD8+<\/span> Cytotoxic T lymphocytes \u2013 kill infected cells<\/div>\n<div><span style=\"background: #4b7ca1;color: white;padding: 0.1rem 0.8rem;border-radius: 30px\">CD4+<\/span> Helper T cells \u2013 support B cells &amp; CD8+<\/div>\n<\/div>\n<\/div>\n<div class=\"grid-2\">\n<div class=\"card\">\n<h4>\ud83d\udcc9 Antibody limitations<\/h4>\n<ul>\n<li>NAb titers decline within months<\/li>\n<li>Variants (Omicron) evade NAb recognition<\/li>\n<\/ul>\n<\/div>\n<div class=\"card\">\n<h4>\ud83d\udcaa T\u2011cell advantages<\/h4>\n<ul>\n<li>&gt;80% T\u2011cell epitopes conserved across variants<\/li>\n<li>Detect infected cells (not just spike RBD)<\/li>\n<li>Prevent severe illness<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<div class=\"card\">\n<h4>\ud83d\udd2c Evidence<\/h4>\n<ul>\n<li>Cancer patients with B\u2011cell defects still protected via CD8+ T cells<\/li>\n<li>Macaque studies: CD8+ depletion removes vaccine protection<\/li>\n<li>South Africa Omicron wave: T cells major protective role<\/li>\n<\/ul>\n<\/div>\n<div class=\"card\">\n<h4>\ud83e\udded Implications for future vaccines<\/h4>\n<ul>\n<li>Broaden efficacy assessment beyond antibody titers<\/li>\n<li>Include conserved proteins (e.g., nucleocapsid) to expand T\u2011cell epitopes<\/li>\n<li>Enhance mucosal T\u2011cell immunity<\/li>\n<\/ul>\n<\/div>\n<div class=\"ref\">\n<p><strong>References<\/strong><br \/>\nWherry, E.J. &amp; Barouch, D.H. (2022). T cell immunity to COVID-19 vaccines. <em>Science<\/em> 377(6608):821\u2011822.<br \/>\nPiano Mortari, E. et al. (2025). T and B cell responses in COVID-19. <em>Front Immunol<\/em> 16:1535014.<\/p>\n<\/div>\n<\/div>\n<p><!-- =============================== --><br \/>\n<!-- PANEL 3: End-of-term Reflection --><br \/>\n<!-- =============================== --><\/p>\n<div id=\"tab-reflection\" class=\"panel\">\n<h2 class=\"section-title\">\ud83d\udcdd End\u2011of\u2011Term Reflection<\/h2>\n<div class=\"reflection-text\">\n<p><strong>Connecting immunology to my biomedical science journey<\/strong><\/p>\n<p>One of the most valuable connections I made in this course was understanding how monoclonal antibodies like Tafasitamab leverage the body&#8217;s own immune mechanisms to fight cancer. I had previously studied cancer biology from the perspective of cellular mutations and uncontrolled division, but this course showed me the therapeutic power of immunology\u2014specifically how ADCC and ADCP can be harnessed as precision tools. This directly connects to my biomedical science coursework in pharmacology and oncology, where we discuss targeted therapies, but rarely delve into the immunological mechanisms that make them effective. Learning about Tafasitamab&#8217;s mechanism of action gave me a concrete example of how antibody engineering translates from bench to bedside, and it reinforced why immunology is foundational to so many emerging cancer treatments. Additionally, the COVID-19 vaccine paper on T cell immunity connected to my virology coursework, showing that sterilizing immunity (antibodies) and disease protection (T cells) are distinct but complementary concepts. This holistic understanding of immune responses has fundamentally changed how I evaluate vaccines and immunotherapies, making me a more critical and informed biomedical science student. Moving forward, I feel better prepared to engage with clinical research and appreciate the immunological rationale behind treatment protocols.<\/p>\n<\/div>\n<div class=\"card\" style=\"margin-top: 1.2rem\">\n<p><strong>Also reflected in BIOL 302 reflections:<\/strong> CAR\u2011T therapy and vaccine mandate discussions further solidified my understanding of immune application in public health and oncology.<\/p>\n<\/div>\n<\/div>\n<p><!-- =============================== --><br \/>\n<!-- PANEL 4: Mid-Term Self-Eval      --><br \/>\n<!-- =============================== --><\/p>\n<div id=\"tab-mid\" class=\"panel\">\n<h2 class=\"section-title\">\ud83d\udccc Mid\u2011Term Self\u2011Evaluation<\/h2>\n<div class=\"card\">\n<h4>\ud83e\udde9 Concepts still unclear<\/h4>\n<p>Alternative complement pathway (initiation\/regulation), C3 convertase as convergent point, MAC nomenclature &amp; function.<\/p>\n<\/div>\n<div class=\"card\">\n<h4>\ud83d\udcda Achieve assignments<\/h4>\n<p>Moderately helpful for general foundation, but sometimes not aligned with exam details (acronyms, specific proteases).<\/p>\n<\/div>\n<div class=\"card\">\n<h4>\ud83d\udcaa Strengths<\/h4>\n<p>Innate immune cells, TLRs\/PRRs, opsonins (CRP), cytokine families. Enjoyed pathogen evasion (e.g., <em>M. tuberculosis<\/em> blocking phagosome\u2011lysosome fusion).<\/p>\n<\/div>\n<div class=\"card\">\n<h4>\ud83d\udcc8 Areas to improve<\/h4>\n<p>Complement pathways, NF\u2011\u03baB signaling, MHC recognition. Alternative pathway most difficult \u2014 properdin, C3 convertase regulation.<\/p>\n<\/div>\n<div class=\"card\">\n<h4>\ud83e\udde0 New study habits<\/h4>\n<p>Active recall &amp; diagram drawing (complement, NF\u2011\u03baB). Redrawing from memory and explaining out loud.<\/p>\n<\/div>\n<div class=\"card\">\n<h4>\ud83d\udcca Exam prep &amp; lost points<\/h4>\n<ul>\n<li>Prep time: ~6\u20118 h per exam<\/li>\n<li>Lost points: lack of understanding (35%), remembering structures (20%), applying definitions (15%)<\/li>\n<li>Will do: more pathway diagrams, self\u2011quizzing, strategic online resources.<\/li>\n<\/ul>\n<\/div>\n<div class=\"card\">\n<h4>\ud83d\udcdd ePortfolio mAb assignment<\/h4>\n<p>Enjoyed researching Tafasitamab; connected to real\u2011world cancer treatment. Grade fair, first draft had informal language \u2014 will improve.<\/p>\n<\/div>\n<\/div>\n<p><!-- =============================== --><br \/>\n<!-- PANEL 5: Vaccine Mandate        --><br \/>\n<!-- =============================== --><\/p>\n<div id=\"tab-vaccine\" class=\"panel\">\n<h2 class=\"section-title\">\ud83d\udc89 Should childhood vaccinations be mandated?<\/h2>\n<div class=\"card\">\n<p><strong>Position:<\/strong> Mandatory for children in public\/private schools, with legal consequences (school access restrictions rather than prosecution).<\/p>\n<ul>\n<li>Vaccines protect individuals and build herd immunity for immunocompromised\/allergic individuals.<\/li>\n<li>Diseases like measles, polio, diphtheria have been drastically reduced.<\/li>\n<li>Parental responsibility must consider community safety.<\/li>\n<li>Medical exceptions should be supported; information campaigns are essential.<\/li>\n<\/ul>\n<div class=\"ref\" style=\"border-top: none;margin-top: 0.8rem\">\n<p>CDC (2025). Vaccines and Immunizations. WHO (2024). Immunization Agenda 2030.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p><!-- =============================== --><br \/>\n<!-- PANEL 6: CAR-T Therapy          --><br \/>\n<!-- =============================== --><\/p>\n<div id=\"tab-car\" class=\"panel\">\n<h2 class=\"section-title\">\ud83e\uddeb CAR T\u2011cell therapy<\/h2>\n<div class=\"card\">\n<p><strong>What:<\/strong> Chimeric Antigen Receptor T\u2011cell therapy \u2014 immunotherapy using patient&#8217;s own T cells to kill cancer.<\/p>\n<ul>\n<li><strong>Where:<\/strong> Specialized hospital \/ cancer center.<\/li>\n<li><strong>How:<\/strong> Leukapheresis \u2192 genetic engineering to express CAR \u2192 expansion \u2192 infusion after chemotherapy.<\/li>\n<li><strong>Whom:<\/strong> B\u2011cell ALL, DLBCL, mantle cell lymphoma, multiple myeloma.<\/li>\n<li><strong>When:<\/strong> First FDA approvals in 2017; ongoing research for solid tumors.<\/li>\n<li><strong>Adverse effects:<\/strong> cytokine release syndrome, neurologic issues.<\/li>\n<\/ul>\n<div class=\"ref\" style=\"border-top: none;margin-top: 0.8rem\">\n<p>FDA approvals 2017; ongoing clinical trials.<\/p>\n<\/div>\n<\/div>\n<div class=\"card\" style=\"background: #eaf2fb\">\n<p><strong>\ud83d\udd17 Connection to immunology course:<\/strong> CAR\u2011T directly applies T\u2011cell biology, MHC\u2011independent recognition, and effector functions \u2014 a prime example of translational immunology.<\/p>\n<\/div>\n<\/div>\n<p><!-- FOOTER --><\/p>\n<div style=\"margin-top: 3rem;padding-top: 1.2rem;border-top: 1px solid #d5dfeb;font-size: 0.9rem;color: #3e5f7a;text-align: center\">\n<p>BIOL 302 \u00b7 Immunology \u00b7 ePortfolio \u00b7 Aayushi Tailor \u00b7 June 2026<\/p>\n<p style=\"font-size: 0.8rem\">All content original, references cited. Published for course completion<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\ud83e\uddec Immunology ePortfolio Aayushi Tailor \u00b7 Biomedical Science \u00b7 June 2026 \u23f3 Final \u00b7 Completion \ud83e\uddea mAb Drug \ud83e\udda0 COVID T-cell \ud83d\udcd8 Reflection \ud83d\udccc Mid-Term Self-Eval \ud83d\udc89 Vaccine Mandate \ud83e\uddeb CAR-T Therapy \ud83d\udc8a Tafasitamab (Monjuvi\u00ae) \u2014 mAb Profile Drug Overview&#8230; <a class=\"more-link\" href=\"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/\">Continue Reading &rarr;<\/a><\/p>\n","protected":false},"author":26596,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"open","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-json\/wp\/v2\/pages\/123"}],"collection":[{"href":"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-json\/wp\/v2\/users\/26596"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-json\/wp\/v2\/comments?post=123"}],"version-history":[{"count":4,"href":"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-json\/wp\/v2\/pages\/123\/revisions"}],"predecessor-version":[{"id":186,"href":"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-json\/wp\/v2\/pages\/123\/revisions\/186"}],"wp:attachment":[{"href":"https:\/\/sites.wp.odu.edu\/immunology-eportfolio\/wp-json\/wp\/v2\/media?parent=123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}